<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kpccz</journal-id><journal-title-group><journal-title xml:lang="ru">Комплексные проблемы сердечно-сосудистых заболеваний</journal-title><trans-title-group xml:lang="en"><trans-title>Complex Issues of Cardiovascular Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-1278</issn><issn pub-type="epub">2587-9537</issn><publisher><publisher-name>Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17802/2306-1278-2018-7-1-6-13</article-id><article-id custom-type="elpub" pub-id-type="custom">kpccz-387</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>КЛИНИЧЕСКАЯ И ПАТОГЕНЕТИЧЕСКАЯ ВЗАИМОСВЯЗЬ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ, САХАРНОГО ДИАБЕТА 2 ТИПА И ОСТЕОПОРОЗА</article-title><trans-title-group xml:lang="en"><trans-title>CLINICAL AND PATHOGENIC RELATIONSHIP BETWEEN CHRONIC HEART FAILURE, TYPE 2 DIABETES MELLITUS AND OSTEOPOROSIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шилов</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shilov</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">newsib54@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тепляков</surname><given-names>А. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Teplyakov</surname><given-names>A. T.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлева</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovleva</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Березикова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Berezikova</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гракова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Grakova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Молоков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Molokov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Неупокоева</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Neupokoeva</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кобец</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kobets</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="en"/><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Копьева</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kopeva</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гармаева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Garmaeva</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное образовательное учреждение высшего образования «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Novosibirsk State Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» «Научно-исследовательский институт кардиологии»<country>Россия</country></aff><aff xml:lang="en">Tomsk National Research Medical Center of the Russian Academy of Sciences, Cardiology Research Institute<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Государственное бюджетное учреждение здравоохранения Новосибирской области «Городская клиническая больница № 1»<country>Россия</country></aff><aff xml:lang="en">City Clinical Hospital №1<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>03</month><year>2018</year></pub-date><volume>7</volume><issue>1</issue><fpage>6</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В., Молоков А.В., Неупокоева М.Н., Кобец В.В., Копьева К.В., Гармаева О.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В., Молоков А.В., Неупокоева М.Н., Кобец В.В., Копьева К.В., Гармаева О.В.</copyright-holder><copyright-holder xml:lang="en">Shilov S.N., Teplyakov A.T., Yakovleva I.V., Popova A.A., Berezikova E.N., Grakova E.V., Molokov A.V., Neupokoeva M.N., Kobets V.V., Kopeva K.V., Garmaeva O.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nii-kpssz.com/jour/article/view/387">https://www.nii-kpssz.com/jour/article/view/387</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить клиническую и патогенетическую взаимосвязь развития хронической сердечной недостаточности (ХСН) ишемического генеза, ассоциированной с сахарным диабетом (СД) 2 типа и остеопорозом у женщин в постменопаузальном периоде, а также оценить влияние антиостеопоретической терапии на течение ХСН.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы.  исследование были включены 178 женщин: 48 женщин – с ХСН и СД 2 типа (группа 1), 93 пациентки – c остеопорозом и ХСН (группа 2), 37 женщин – с остеопорозом, ХСН и СД 2 типа (группа 3). В группу контроля вошли 35 женщин, находящихся в постменопаузе, без клинических и инструментальных признаков патологии сердечно-сосудистой системы, СД и остеопоротического процесса. Во 2-й группе у 35 женщин для лечения остеопороза применялись препараты, относящиеся к группе бисфосфонатов. Определение концентрации фактора некроза опухоли-α (ФНО-α), интерлейкина-1β (ИЛ-1β) и остеопротегерина в сыворотке крови проводилось методом твердофазного иммуноферментного анализа.</p></sec><sec><title>Результаты</title><p>Результаты. Показана достоверная обратная зависимость между уровнями общего холестерина, триглицеридов и липопротеидов низкой плотности, а также уровнями артериального давления и минеральной плотности кости. Концентрация ФНО-α и ИЛ-1β была достоверно выше в группе 3 по сравнению с пациентками групп 1 и 2. Женщины контрольной группы имели достоверно более низкие уровни цитокинов по сравнению с больными всех групп наблюдения. Во всех группах женщин с коморбидной патологией концентрация остеопротегерина была достоверно выше, чем в группе контроля. Концентрация ФНО-α, ИЛ-1β, остеопротегерина и уровень гликированного гемоглобина достоверно обратно коррелировали с минеральной плотностью кости и имели прямую корреляционную зависимость с тяжестью течения ХСН. Выявлены значимые ассоциации уровней ФНО-α и ИЛ-1β и сниженной минеральной плотности кости с неблагоприятным течением ХСН. Также выявлена значимая ассоциация терапии бисфосфонатами с благоприятным течением ХСН.</p></sec><sec><title>Заключение</title><p>Заключение. Пошенная продукция цитокинов и остеопротегерина имеет важное значение в развитии коморбидной патологии, включающей ХСН, СД 2 типа и остеопороз. Расшифровка механизмов, определяющих связь между развитием данных заболеваний, имеет существенное значение для разработки новых подходов к изучению факторов риска, разработки новых методов профилактики и лечения этих заболеваний.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim.. To study clinical and pathogenic relationships between the development of chronic heart failure (CHF) of ischemic genesis associated with type 2 diabetes mellitus (DM) and osteoporosis in postmenopausal women and to evaluate the effects of anti-osteoporotic therapy on CHFMethods</p></sec><sec><title>Methods</title><p>Methods. A total of 178 women were recruited in the study. All patients were assigned to three groups: Group 1 (n = 48) women with CHF and type 2 DM, Group 2 (n = 93) – women with osteoporosis and CHF, Group 3 (n = 37) women with osteoporosis, heart failure and type 2 diabetes mellitus. The control group comprised 35 healthy women in postmenopausal period without clinical signs and symptoms of cardiovascular disease, diabetes and osteoporotic process. 35 patients in Group 2 received bisphosphonates for the treatment of osteoporosis. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and osteoprotegerin were measured with the ELISA.</p></sec><sec><title>Results</title><p>Results. A significant inverse correlation between levels of total cholesterol, triglycerides and low-density lipoproteins, blood pressure, and bone mineral density has been found. Levels of TNF-α and IL-1β were significantly higher in Group 3 compared with patients in Groups 1 and 2. Women in the control group had significantly lower levels of cytokines compared with patients in all study groups. All women with comorbidities had significantly higher levels of osteoprotegerin compared with the control group. A significant inverse correlation between levels of TNF-α, IL-1β, osteoprotegerin and glycated hemoglobin and bone mineral density has been determined, as well as a direct correlation with the severity of CHF. A significant association between levels of TNF-α and IL-1β, and reduced bone mineral density and unfavorable course of CHF has been established as well. A significant association between bisphosphonates therapy and a favorable course of CHF has been identified.</p></sec><sec><title>Conclusion</title><p>Conclusion. Increased production of cytokines and osteoprotegerin is of crucial importance for the development of comorbidities, including CHF, type 2 diabetes mellitus and osteoporosis. Understanding of the key mechanisms determining the relationships between these diseases is essential for the development of novel approaches for evaluating risk factors and new methods for prevention and treatment of these diseases.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>остеопороз</kwd><kwd>сахарный диабет</kwd><kwd>коморбидность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>osteoporosis</kwd><kwd>diabetes mellitus</kwd><kwd>comorbidity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kraemer H.C. Statistical issues in assessing comorbidity. Stat Med. 1995; 14: 721-723.</mixed-citation><mixed-citation xml:lang="en">Kraemer H.C. Statistical issues in assessing comorbidity. Stat Med. 1995; 14: 721-723.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Akker M., Buntinx F., Roos S., Knottnerus J.A. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract. 1996; 2 (2): 65-70.https://doi.org/10.3109/13814789609162146</mixed-citation><mixed-citation xml:lang="en">Van den Akker M., Buntinx F., Roos S., Knottnerus J.A. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract. 1996; 2 (2): 65-70.https://doi.org/10.3109/13814789609162146</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012; 60(10):E1-E25. doi: 10.1111/j.1532-5415.2012.04188.x.</mixed-citation><mixed-citation xml:lang="en">Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012; 60(10):E1-E25. doi: 10.1111/j.1532-5415.2012.04188.x.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ширинский В.С, Ширинский И.В. Коморбидные заболевания – актуальная проблема клинической медицины. Сибирский медицинский журнал. 2014; 29 (1): 7-12.</mixed-citation><mixed-citation xml:lang="en">Shirinsky V.S., Shirinsky I.V. Comorbid disease as an important problem of clinical medicine. The Siberian Medical Journal. 2014; 29 (1): 7-12. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Association of cardiometabolic multimorbidity with mortality. JAMA. 2015; 314 (1): 52-60. doi: 10.1001/jama.2015.7008.</mixed-citation><mixed-citation xml:lang="en">Association of cardiometabolic multimorbidity with mortality. JAMA. 2015; 314 (1): 52-60. doi: 10.1001/jama.2015.7008.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kongkaew C., Noyce P.R., Ashcroft D.M. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42 (7): 1017-1025. doi: 10.1345/aph.1L037</mixed-citation><mixed-citation xml:lang="en">Kongkaew C., Noyce P.R., Ashcroft D.M. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42 (7): 1017-1025. doi: 10.1345/aph.1L037</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang M., Holman C.D., Price S.D., Sanfilippo F.M., Preen D.B., Bulsara M.K. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009; 338: a2752. doi: 10.1136/bmj.a2752.</mixed-citation><mixed-citation xml:lang="en">Zhang M., Holman C.D., Price S.D., Sanfilippo F.M., Preen D.B., Bulsara M.K. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009; 338: a2752. doi: 10.1136/bmj.a2752.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Olmos L., Salvador C.H., Alberquilla A., L. David, C. Montserrat, G.-S. Pilar et al. Comorbidity patterns in patients with chronic diseases in general practice. PLoS One. 2012; 7(2): e32141. doi: 10.1371/journal.pone.0032141</mixed-citation><mixed-citation xml:lang="en">Garcia-Olmos L., Salvador C.H., Alberquilla A., L. David, C. Montserrat, G.-S. Pilar et al. Comorbidity patterns in patients with chronic diseases in general practice. PLoS One. 2012; 7(2): e32141. doi: 10.1371/journal.pone.0032141</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301 (5): 513-521. doi: 10.1001/jama.2009.50.</mixed-citation><mixed-citation xml:lang="en">Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301 (5): 513-521. doi: 10.1001/jama.2009.50.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Тепляков А.Т., Болотская Л.А., Степачева Т.А., Караман Н.В., Рыбальченко Е.В., Шилов С.Н., Маслов А.П. Супрессивное влияние рекомбинантного иммуномодулятора ронколейкина на уровень провоспалительных цитокинов, аутоантител к кардиолипину в крови и сердечную недостаточность. Кардиология. 2008; 48 (8): 34-40.</mixed-citation><mixed-citation xml:lang="en">Teplyakov A.T., Bolotskaya L.A., Stepatcheva T.A., Karaman N.V., Rybal’chenko E.V., Shilov S.N., Maslov A.P. Suppressive Effect of Recombinant Immunomodulator Ronkoleukinonthe Blood Levelof Antiinflammatory Cytokines, Anticardiolipin Autoantibodies and Heart Failure. Kardiologiia. 2008; 48 (8): 34-40. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Farhat G.N., Cauley J.A. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2008; 5: 19-34.</mixed-citation><mixed-citation xml:lang="en">Farhat G.N., Cauley J.A. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2008; 5: 19-34.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Anagnostis P., Karagiannis A., Kakafika A.I., Tziomalos K., Athyros V.G., Mikhailidis D.P. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 2009; 20: 197-207. doi: 10.1007/s00198-008-0648-5</mixed-citation><mixed-citation xml:lang="en">Anagnostis P., Karagiannis A., Kakafika A.I., Tziomalos K., Athyros V.G., Mikhailidis D.P. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 2009; 20: 197-207. doi: 10.1007/s00198-008-0648-5</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Farhat G.N., Newman A.B., Sutton-Tyrrell K., Matthews K.A., Boudreau R., Schwartz A.V., et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int. 2007; 18: 999-1008. doi: 10.1007/s00198-007-0338-8</mixed-citation><mixed-citation xml:lang="en">Farhat G.N., Newman A.B., Sutton-Tyrrell K., Matthews K.A., Boudreau R., Schwartz A.V., et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int. 2007; 18: 999-1008. doi: 10.1007/s00198-007-0338-8</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Den Uyl D., Nurmohamed M.T., van Tuyl L.H., Raterman H.G., Lems W.F. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011; 13: R5. doi: 10.1186/ar3224</mixed-citation><mixed-citation xml:lang="en">Den Uyl D., Nurmohamed M.T., van Tuyl L.H., Raterman H.G., Lems W.F. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011; 13: R5. doi: 10.1186/ar3224</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mezquita-Raya P., de la Higuera M., Garcı´a D.F., Alonso G., RuizRequena M.E., de Dios Luna J. et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005; 16: 1368-1374. doi: 10.1007/s00198-005-1844-1</mixed-citation><mixed-citation xml:lang="en">Mezquita-Raya P., de la Higuera M., Garcı´a D.F., Alonso G., RuizRequena M.E., de Dios Luna J. et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005; 16: 1368-1374. doi: 10.1007/s00198-005-1844-1</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lampropoulos C.E., Kalamara P., Konsta M., Papaioannou I., Papadima E., Antoniou Z. et al. Osteoporosis and vascular calcification in postmenopausal women: a cross-sectional study. Climacteric. 2016; 19: 303307. doi: 10.3109/13697137.2016.1164134</mixed-citation><mixed-citation xml:lang="en">Lampropoulos C.E., Kalamara P., Konsta M., Papaioannou I., Papadima E., Antoniou Z. et al. Osteoporosis and vascular calcification in postmenopausal women: a cross-sectional study. Climacteric. 2016; 19: 303307. doi: 10.3109/13697137.2016.1164134</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Seven A., Yuksel B., Kabil K.S., Yavuz G., Polat M., Unlu B.S., Keskin N. The evaluation of hormonal and psychological parameters that affect bone mineral density in postmenopausal women. Eur Rev Med Pharmacol Sci. 2016; 20: 20-25.</mixed-citation><mixed-citation xml:lang="en">Seven A., Yuksel B., Kabil K.S., Yavuz G., Polat M., Unlu B.S., Keskin N. The evaluation of hormonal and psychological parameters that affect bone mineral density in postmenopausal women. Eur Rev Med Pharmacol Sci. 2016; 20: 20-25.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tanko L.B., Christiansen C., Cox D.A., Geiger M.J., McNabb M.A., Cummings S.R. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20: 1912-1920. doi: 10.1359/JBMR.050711</mixed-citation><mixed-citation xml:lang="en">Tanko L.B., Christiansen C., Cox D.A., Geiger M.J., McNabb M.A., Cummings S.R. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20: 1912-1920. doi: 10.1359/JBMR.050711</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin M.R., Silverberg S.J. Vascular calcification and osteoporosisthe nature of the nexus. J Clin Endocrinol Metab. 2004; 89: 4243-4245. doi: 10.1210/jc.2004-1324</mixed-citation><mixed-citation xml:lang="en">Rubin M.R., Silverberg S.J. Vascular calcification and osteoporosisthe nature of the nexus. J Clin Endocrinol Metab. 2004; 89: 4243-4245. doi: 10.1210/jc.2004-1324</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fiore C.E., Pennisi P., Pulvirenti I., Francucci CM.Bisphosphonates and atherosclerosis. J Endocrinol Invest. 2009; 32: 38-43.</mixed-citation><mixed-citation xml:lang="en">Fiore C.E., Pennisi P., Pulvirenti I., Francucci CM.Bisphosphonates and atherosclerosis. J Endocrinol Invest. 2009; 32: 38-43.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Strandberg T.E. Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med. 2008; 168: 2386-2387. doi: 10.1001/archinte.168.21.2386-c</mixed-citation><mixed-citation xml:lang="en">Strandberg T.E. Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med. 2008; 168: 2386-2387. doi: 10.1001/archinte.168.21.2386-c</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ariyoshi T., Eishi K., Sakamoto I., Matsukuma S., Odate T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006; 26: 215-222.</mixed-citation><mixed-citation xml:lang="en">Ariyoshi T., Eishi K., Sakamoto I., Matsukuma S., Odate T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006; 26: 215-222.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kang J.H., Keller J.J., Lin H.C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013; 24: 271-277. doi: 10.1007/s00198-012-2213-5</mixed-citation><mixed-citation xml:lang="en">Kang J.H., Keller J.J., Lin H.C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013; 24: 271-277. doi: 10.1007/s00198-012-2213-5</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Horowitz M. Matrix proteins versus cytokines in the regulation of osteoblast function and bone formation. Calcif Tissue Int. 2003; 72: 5-7. https://doi.org/10.1007/s00223-002-1048-z</mixed-citation><mixed-citation xml:lang="en">Horowitz M. Matrix proteins versus cytokines in the regulation of osteoblast function and bone formation. Calcif Tissue Int. 2003; 72: 5-7. https://doi.org/10.1007/s00223-002-1048-z</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Shapses S.A., Pop L.C., Wang Y. Obesity is a concern for bone health with aging. Nutr Res. 2017; 9: 1-13. doi: 10.1016/j.nutres.2016.12.010</mixed-citation><mixed-citation xml:lang="en">Shapses S.A., Pop L.C., Wang Y. Obesity is a concern for bone health with aging. Nutr Res. 2017; 9: 1-13. doi: 10.1016/j.nutres.2016.12.010</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
